The Use of Cannabis (Marijuana) and Cannabidiol (CBD) Among Cancer Patients: A Pilot Study
April 13, 2026 updated by: M.D. Anderson Cancer Center
To collect information about how patients in the pain management clinic use cannabis/CBD, including how often it is used, why it is used (for example, to manage pain or other symptoms), and where patients get their information on cannabis/CBD for pain management
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Objectives
Primary Objective:
The primary objective of this study is to investigate the prevalence of current and prior cannabis and/or CBD use in cancer patients who present to the pain management clinic at MDACC.
Secondary Objectives:
The secondary objective is to investigate the reason for cannabis/CBD use (e.g. pain, neuropsychiatric symptoms, recreational or other use), degree of symptom improvement with use, frequency of use, methods of use (e.g. inhaled vs. ingested), sources of information on cannabis/CBD, and patient interest in learning more from their physicians about cannabis/CBD for cancer pain.
Study Type
Observational
Enrollment (Estimated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
M D Anderson Cancer Center
Description
Inclusion Criteria:
- Age 18 years or older
- Cancer patients who present to the MD Anderson Pain Medicine Clinic as a new patient or consult
- Willing to give informed consent
- Willing to complete the survey
Exclusion Criteria:
- Refusal of informed consent
- Refusal to complete the survey
- Patients who previously completed the survey
- Patients who opt-out or change their mind after agreeing to participate
- Already an established patient at MDACC Pain Medicine Clinic
- Patients scheduled to see Dr Abdi (PI).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Cannabis (Marijuana) and Cannabidiol (CBD)
This is a survey to determine the number of cancer pain patients who use and/or used Marijuana and/or CBD for pain or other symptom burdens.
|
The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education.
The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cannabis (Marijuana) and CBD (Cannabidiol for Cancer Pain Survey
Time Frame: through study completion; an average of 1 year.
|
Score scale ranges from 1-5, Extremely interested(1),Not Interested (5)
|
through study completion; an average of 1 year.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Salahadin Abdi, MD,PHD, M.D. Anderson Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 30, 2023
Primary Completion (Estimated)
May 31, 2027
Study Completion (Estimated)
May 31, 2027
Study Registration Dates
First Submitted
April 19, 2023
First Submitted That Met QC Criteria
April 20, 2023
First Posted (Actual)
May 1, 2023
Study Record Updates
Last Update Posted (Actual)
April 16, 2026
Last Update Submitted That Met QC Criteria
April 13, 2026
Last Verified
April 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-0049
- NCI-2023-03440 (Other Identifier: NCI-CTRP Clinical Trials Registry)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.